Intraparenchymal Umbilical Cord Mesenchymal Stem Cell Transplantation in Patients with Subacute Ischemic Stroke: A Preliminary Study of Safety and Early Clinical Outcomes

BACKGROUND: Intravenous thrombolysis and mechanical thrombectomy are current standard treatments for ischemic stroke, however their narrow therapeutic window limits eligibility for many patients. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) have emerged as a promising regenerative therapy, but their safety and efficacy need to be further elucidated. Interleukin-6 (IL-6) and brain-derived neurotrophic factor (BDNF) may provide biological insights into the inflammatory and neuroregenerative responses following UC-MSC transplantation. This study was conducted to evaluate the safety and preliminary efficacy, including IL-6 and BDNF level, after stereotactic intraparenchymal UC-MSC transplantation.METHODS: Subjects with subacute ischemic stroke received stereotactic intraparenchymal transplantation of 2×10⁷ allogeneic UC-MSCs into the perolesional ischemic area, 13 to 20 days after stroke onset. Safety was assessed by monitoring the adverse events. Early efficacy was evaluated using the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Magnetic Resonance Imaging (MRI), and serum biomarkers, including IL-6 and BDNF. Serum IL-6 levels were measured using electrochemiluminescence immunoassay (ECLIA), while BDNF levels were measured using enzyme-linked immunosorbent assay (ELISA).RESULTS: No serious adverse events related to UC-MSCs administration were observed during the three-month follow-up. No serious adverse events related to UC-MSC administration were observed during the three-month follow-up. From baseline to the third month, improved mRS and NIHSS scores were observed (mean Δ: −0.75 and +4.00, respectively), along with reduced IL-6 (mean Δ: −2.76 pg/mL) and increased BDNF (mean Δ: +3.16 ng/mL).CONCLUSION: UC-MSC transplantation was well tolerated, with improvements in NIHSS and mRS and favorable changes in IL-6 and BDNF levels. These findings suggest that direct intraparenchymal UC-MSCs transplantation may be safe, as no severe adverse events were observed in this preliminary study.KEYWORDS: ischemic stroke, umbilical cord-derived mesenchymal stem cells (UC-MSCs), interleukin-6, brain-derived neurotrophic factor

Authors

Institutions

Publication Details

Journal
The Indonesian Biomedical Journal
Published
2026-11-14
DOI
https://doi.org/10.18585/inabj.v18i5.4281
Primary Topic
Mesenchymal stem cell research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Intraparenchymal Umbilical Cord Mesenchymal Stem Cell Transplantation in Patients with Subacute Ischemic Stroke: A Preliminary Study of Safety and Early Clinical Outcomes

Erin Triani, Rima Haifa, Cynthia Retna Sartika, Keri Lestari et al.
The Indonesian Biomedical Journal
Mesenchymal stem cell research
article

Intraparenchymal Umbilical Cord Mesenchymal Stem Cell Transplantation in Patients with Subacute Ischemic Stroke: A Preliminary Study of Safety and Early Clinical Outcomes

Erin Triani, Rima Haifa, Cynthia Retna Sartika, Keri Lestari, Ahmad Faried, Andi Wijaya, Nisa Zulfani, Rafa Fauziah, Muhammad Agus Aulia
article en

Abstract

BACKGROUND: Intravenous thrombolysis and mechanical thrombectomy are current standard treatments for ischemic stroke, however their narrow therapeutic window limits eligibility for many patients. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) have emerged as a promising regenerative therapy, but their safety and efficacy need to be further elucidated. Interleukin-6 (IL-6) and brain-derived neurotrophic factor (BDNF) may provide biological insights into the inflammatory and neuroregenerative responses following UC-MSC transplantation. This study was conducted to evaluate the safety and preliminary efficacy, including IL-6 and BDNF level, after stereotactic intraparenchymal UC-MSC transplantation.METHODS: Subjects with subacute ischemic stroke received stereotactic intraparenchymal transplantation of 2×10⁷ allogeneic UC-MSCs into the perolesional ischemic area, 13 to 20 days after stroke onset. Safety was assessed by monitoring the adverse events. Early efficacy was evaluated using the National Institutes of Health Stroke Scale (NIHSS), modified Rankin Scale (mRS), Magnetic Resonance Imaging (MRI), and serum biomarkers, including IL-6 and BDNF. Serum IL-6 levels were measured using electrochemiluminescence immunoassay (ECLIA), while BDNF levels were measured using enzyme-linked immunosorbent assay (ELISA).RESULTS: No serious adverse events related to UC-MSCs administration were observed during the three-month follow-up. No serious adverse events related to UC-MSC administration were observed during the three-month follow-up. From baseline to the third month, improved mRS and NIHSS scores were observed (mean Δ: −0.75 and +4.00, respectively), along with reduced IL-6 (mean Δ: −2.76 pg/mL) and increased BDNF (mean Δ: +3.16 ng/mL).CONCLUSION: UC-MSC transplantation was well tolerated, with improvements in NIHSS and mRS and favorable changes in IL-6 and BDNF levels. These findings suggest that direct intraparenchymal UC-MSCs transplantation may be safe, as no severe adverse events were observed in this preliminary study.KEYWORDS: ischemic stroke, umbilical cord-derived mesenchymal stem cells (UC-MSCs), interleukin-6, brain-derived neurotrophic factor

The Indonesian Biomedical JournalVol. 18(5)
Padjadjaran University (ID)
Mesenchymal stem cell research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon